Jericho sciences

SMALL MOLECULE FOR CURING CHRONIC HEPATITIS B VIRUS INFECTION

www.jerichosciences.com | 703-862-1700 | heidi@jerichosciences.com

Unmet Need

Chronic Hepatitis B virus **(HBV)** infection remains a major global public health burden, impacting ~**300 million people worldwide**. Chronic HBV is a leading cause of liver diseases, including **hepatocellular carcinoma, cirrhosis & liver failure**, resulting in over **1 million deaths** each year. There are currently **no** approved drugs to cure chronic HBV. Achieving a complete cure will require inactivating and eliminating the source of its persistence - the HBV covalently closed circular DNA, or **cccDNA**.

Market Opportunity

SOM (U.S)
$600M
14,000 new patients/yr at $42K

SAM (U.S)
$67B
1.6M people at $42K

TAM (Global)
$6.3T
300M people at $21K per course of treatment

Value Proposition

Jericho Sciences is developing a lead small molecule of a **new drug class** & **mechanism of action** with a good preclinical safety profile useful for **curing chronic HBV** infection by inactivating & reducing the **HBV cccDNA** responsible for its persistence.

Solution

HBV cccDNA is the primary obstacle to achieving a cure and is refractory to current standard of care therapies. **JS103, our lead small molecule,** demonstrates curative antiviral activities in primary HBV-infected human liver cells, with a safety margin > 50 (CC50/EC50).

Competition

Currently available drugs are **not curative** & only limit new virus production. Approaches in clinical testing to cure HBV infection include combinations of antibodies, immunomodulators, oligotherapies and gene-editing therapies that have not achieved curative outcomes for regulatory approval.

Traction

- Patent Filed 2023; Inventor & Assignee
- $4M Non-Dilutive NIH/SBA Support
- Supportive Preclinical Safety Data
- New 2-Yr NIH Small Business Grant 2025
- **$1.2M Seed Round Use Of Funds**



Exit Strategy

License following Phase 1b/2a clinical studies within 4 years. Qualifying **Fast Track** FDA INDA with **Breakthrough Therapy** Designation marketable after Phase 2b and FDA approval.

Jericho's Team

Heidi Kay, PhD: Founder, Inventor and CEO
Haitao Guo, PhD: HBV Researcher/KOL at UPitt
Esther Alegria, PhD & MBA: Pharma Strategist
Marco Schito, PhD: Regulatory Expert, Virologist
Deanna Kulpa, PhD: Virus Researcher at Emory
Joe Sebastian, PhD: Clinical Diagnostic Expert
Mark Zorko, MBA, & CPA: Financial Expert
Shane Cortesi, PA: Patent & Legal Advisor